Effect of tocilizumab on endothelial and platelet-derived CXC-chemokines and their association with inflammation and myocardial injury in STEMI patients undergoing primary PCI
This study suggests that the beneficial effects of tocilizumab in STEMI patients are not due to changes in circulating endothelial or platelet-derived CXC-chemokines, compared to placebo. However, heparin significantly influences the levels of these chemokines.
Authors
- Geir Øystein Andersen (ORCID: https://orcid.org/0000-0003-1578-6440)
- Pål Aukrust
- Lars Gullestad (ORCID: https://orcid.org/0000-0002-5932-6641)
- Kaspar Broch (ORCID: https://orcid.org/0000-0003-4316-805X)
- Sindre Woxholt (ORCID: https://orcid.org/0000-0002-8512-9609)
- Bente Lise Halvorsen (ORCID: https://orcid.org/0000-0002-6529-6485)
- Ola Kleveland
- Thor Ueland (ORCID: https://orcid.org/0000-0001-5005-0784)
- Jan Kristian Damås (ORCID: https://orcid.org/0000-0003-4268-671X)
- Rune Wiseth (ORCID: https://orcid.org/0000-0002-5097-4554)
- Anne Kristine Anstensrud (ORCID: https://orcid.org/0000-0003-1499-2402)
- Ingebjørg Seljeflot (ORCID: https://orcid.org/0000-0003-4071-3358)
- Camilla Huse (ORCID: https://orcid.org/0000-0002-7694-5196)
- Tuva Børresdatter Dahl (ORCID: https://orcid.org/0000-0001-7818-9411)
- Ingvild Maria Tøllefsen (ORCID: https://orcid.org/0000-0003-4972-3093)
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- St Olav's University Hospital (NO)
Publication Details
- Journal
- International Journal of Cardiology
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1016/j.ijcard.2024.132613
- Citations
- 4
- Primary Topic
- Atherosclerosis and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.96
Funders
- F. Hoffmann-La Roche
- Helse Midt-Norge
- Helse Sør-Øst RHF